IL22 and head and neck squamous cell carcinoma: Examining the validated antitumor activity in MUC1-targeting CAR-T cells, and in CAR-MUC1-IL-22-T cells secreting IL-22, CAR-MUC1-IL-22-T cells have exhibited higher cytotoxicity against MUC1+HNSCC cells.